Ota, Hikaru
Takeuchi, Jun
Nakano, Yuyako
Horiguchi, Etsuyo
Taki, Yosuke
Ito, Yasuki
Terasaki, Hiroko
Nishiguchi, Koji M.
Kataoka, Keiko http://orcid.org/0000-0002-8795-6536
Article History
Received: 16 November 2021
Accepted: 28 January 2022
First Online: 2 March 2022
Conflicts of interest
: H. Ota, None; J. Takeuchi, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Santen, Bayer); Y. Nakano, None; E. Horiguchi, None; Y. Taki, None; Y. Ito, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Bayer, Canon, ZEISS, Kowa, Novartis, Pfizer, Santen); H. Terasaki, Grant (ZEISS, Kowa, Otsuka, Senju, Santen, Alcon, Sanofi, Novartis, ROHTO, Bayer, Wakamoto, HOYA, Johnson&Johnson), Consulting fees (Bayer), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Otsuka, Kowa, Santen, Senju, Sanofi, Alcon, ROHTO, Novartis, Wakamoto, Bayer), Support for attending meetings and/or travel (Bayer); K. M. Nishiguchi, Grant (Takara Bio, Takeda, JCR Pharma, Alcon, Bayer, Novartis, Santen), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Alcon, Bayer, Novartis, Santen, Chugai, Kowa, Senju, Otsuka, Wakamoto), Patents planned, issued or pending (A gene therapy using genome editing with a single AAV vector); K. Kataoka, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Senju, Santen, Bayer, Boehringer Ingelheim, Bayer).